USD573M in retained losses and a less than great 2020!. 2021 a year that cannot get worse, page-32

why do you think it’s up to me to explain away Mesoblast reporting an effect on a sub group in their P3 trial when it is exactly the opposite of what they reported in their P2 trial on the same indication using the same agent. Surely, you’d be better off asking them that?

I’ll write it for you:

”Dear MESO,

why should I believe your 2 pager market announcement on your multi hundreds of millions of $$ CHF trial that you found an affect on a small sub-group, the least sickest patients when you designed the same trial after reporting to the market the drug has an affect on the sickest patients in your FAILED P2 trial in 2015?

how do you explain that?

thanks
Gullible

PS: how come you report every single trial result as a success in your market announcements since 2009 yet have not been able to register a single indication???”